title: The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access.
abstract: Previous work suggests a role for dopamine D3-like receptors in psychostimulant reinforcement. The development of new compounds acting selectively at dopamine D3 receptors has opened new possibilities to explore the role of these receptors in animal models of psychostimulant dependence. Here we investigated whether the dopamine D3 partial agonist CJB090 (1-10 mg/kg, i.v) and the D3 antagonist PG01037 (8-32 mg/kg, s.c.) modified methamphetamine (0.05 mg/kg/injection) intravenous self-administration under fixed- (FR) and progressive- (PR) ratio schedules in rats allowed limited (short access, ShA; 1-hour sessions 3 days/week) or extended access (long access, LgA; 6 hour sessions 6 days/week). Under a FR1 schedule, the highest dose of the D3 partial agonist CJB090 selectively reduced methamphetamine self-administration in LgA but not in ShA rats, whereas the full D3 antagonist PG01037 produced no effect in either group. Under a PR schedule of reinforcement, the D3 partial agonist CJB090 reduced the maximum number of responses performed ('breakpoint') for methamphetamine in LgA rats at the doses of 5 and 10 mg/kg, and also it produced a significant reduction in the ShA group at the highest dose. However, the D3 full antagonist PG01037 only reduced PR methamphetamine self-administration in LgA rats at the highest dose of 32 mg/kg with no effect in the ShA group. The results suggest that rats might be more sensitive to pharmacological modulation of dopamine D3 receptors following extended access to methamphetamine self-administration, opening the possibility that D3 receptors play a role in excessive methamphetamine intake.
authors.affiliation: The Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA 92037, USA. lorio@scripps.edu
authors.forename: Laura
authors.initials: L
authors.lastname: Orio
authors.forename: Sunmee
authors.initials: S
authors.lastname: Wee
authors.forename: Amy H
authors.initials: AH
authors.lastname: Newman
authors.forename: Luigi
authors.initials: L
authors.lastname: Pulvirenti
authors.forename: George F
authors.initials: GF
authors.lastname: Koob
mesh_terms: D019969:Amphetamine-Related Disorders / Q000503:physiopathology*; D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D015259:Dopamine Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D007262:Infusions, Intravenous; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology*; D009042:Motivation / Q000187:drug effects*; D010879:Piperazines / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D050637:Receptors, Dopamine D3 / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000502:physiology; D012055:Reinforcement Schedule; D012646:Self Administration
chemical_list: D001549:Benzamides; D000697:Central Nervous System Stimulants; D015259:Dopamine Agents; C497150:N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)but-2-enyl)-4-pyridine-2-ylbenzamide; C545833:N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide; D010879:Piperazines; D011725:Pyridines; D050637:Receptors, Dopamine D3; D008694:Methamphetamine
references.citation: Neuropsychopharmacology. 2003 Feb;28(2):329-38
references.pmid: 12589386
references.citation: Annu Rev Pharmacol Toxicol. 2007;47:681-98
references.pmid: 17209801
references.citation: Drug Alcohol Rev. 2008 May;27(3):229-35
references.pmid: 18368603
references.citation: Neuropsychopharmacology. 2003 Nov;28(11):1903-15
references.pmid: 12915863
references.citation: West J Med. 1990 Dec;153(6):625-8
references.pmid: 2293467
references.citation: Neuropharmacology. 2005 Sep;49(4):525-41
references.pmid: 15963538
references.citation: J Neurosci. 2002 Nov 1;22(21):9595-603
references.pmid: 12417684
references.citation: Eur J Neurosci. 2002 Jun;15(12):2016-26
references.pmid: 12099907
references.citation: Nature. 1990 Sep 13;347(6289):146-51
references.pmid: 1975644
references.citation: NIDA Res Monogr. 1994;145:1-18
references.pmid: 8742805
references.citation: Drugs. 2004;64(14):1547-73
references.pmid: 15233592
references.citation: Pharmacol Biochem Behav. 2006 Mar;83(3):403-9
references.pmid: 16647107
references.citation: Drugs. 2009 Jul 9;69(10):1319-38
references.pmid: 19583451
references.citation: J Pharmacol Exp Ther. 1998 Sep;286(3):1231-8
references.pmid: 9732383
references.citation: J Pharmacol Exp Ther. 1995 Jul;274(1):90-6
references.pmid: 7616454
references.citation: Neuroreport. 2004 Oct 5;15(14):2245-9
references.pmid: 15371743
references.citation: Pharmacol Biochem Behav. 1990 Aug;36(4):745-9
references.pmid: 2217500
references.citation: Psychopharmacology (Berl). 2006 May;186(1):48-53
references.pmid: 16552556
references.citation: Drug Alcohol Depend. 2006 Jan 4;81(1):63-70
references.pmid: 16005579
references.citation: J Neurosci. 1996 Oct 1;16(19):6100-6
references.pmid: 8815892
references.citation: Cochrane Database Syst Rev. 2009 Jul 08;(3):CD002025
references.pmid: 19588330
references.citation: Science. 1998 Oct 9;282(5387):298-300
references.pmid: 9765157
references.citation: Neuropsychopharmacology. 2005 Apr;30(4):720-30
references.pmid: 15562293
references.citation: Neuroscience. 2006 Oct 13;142(2):515-25
references.pmid: 16876329
references.citation: J Pharmacol Exp Ther. 2008 May;325(2):691-7
references.pmid: 18305018
references.citation: Science. 1993 Jun 18;260(5115):1814-6
references.pmid: 8099761
references.citation: Synapse. 2007 Apr;61(4):216-20
references.pmid: 17230548
references.citation: J Neurosci. 2009 Apr 15;29(15):4846-57
references.pmid: 19369553
references.citation: Neuron. 2008 Jul 10;59(1):11-34
references.pmid: 18614026
references.citation: Bioorg Med Chem Lett. 2003 Jul 7;13(13):2179-83
references.pmid: 12798330
references.citation: J Pharmacol Exp Ther. 2009 Apr;329(1):210-7
references.pmid: 19136638
references.citation: J Med Chem. 2005 Feb 10;48(3):839-48
references.pmid: 15689168
references.citation: CNS Neurol Disord Drug Targets. 2008 Nov;7(5):410-21
references.pmid: 19128200
references.citation: Drug Metab Dispos. 1993 Jul-Aug;21(4):717-23
references.pmid: 8104133
references.citation: J Neurosci. 2007 Oct 17;27(42):11442-50
references.pmid: 17942739
references.citation: J Pharmacol Exp Ther. 2007 May;321(2):573-82
references.pmid: 17272677
references.citation: Neuropsychopharmacology. 2005 Feb;30(2):350-9
references.pmid: 15483561
references.citation: Neuropharmacology. 2009;56 Suppl 1:3-8
references.pmid: 18617195
references.citation: Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8155-9
references.pmid: 1518841
references.citation: Arch Neurol. 2006 Jul;63(7):969-73
references.pmid: 16831966
references.citation: Drug Alcohol Rev. 2008 May;27(3):243-52
references.pmid: 18368605
references.citation: J Clin Psychopharmacol. 1995 Feb;15(1):63-78
references.pmid: 7714230
references.citation: Neuroreport. 2002 Jan 21;13(1):173-6
references.pmid: 11924883
references.citation: Mol Pharmacol. 1999 Nov;56(5):1025-30
references.pmid: 10531409
references.citation: Trends Pharmacol Sci. 1993 Jul;14(7):270-5
references.pmid: 8105597
references.citation: Neuroreport. 2003 Dec 2;14(17):2229-32
references.pmid: 14625453
references.citation: Psychopharmacology (Berl). 2009 Sep;206(1):73-84
references.pmid: 19513698
references.citation: Psychopharmacology (Berl). 2003 Feb;166(1):19-32
references.pmid: 12525958
references.citation: Neuropsychopharmacology. 2001 Mar;24(3):333-6
references.pmid: 11256359
references.citation: Psychopharmacology (Berl). 2004 Apr;172(4):450-4
references.pmid: 14647962
references.citation: Synapse. 2005 Jul;57(1):17-28
references.pmid: 15858839
references.citation: Nat Rev Drug Discov. 2009 Jun;8(6):500-15
references.pmid: 19483710
references.citation: Alcohol Clin Exp Res. 2008 Nov;32(11):1954-61
references.pmid: 18782344
references.citation: Behav Pharmacol. 2001 Feb;12(1):1-11
references.pmid: 11270507
references.citation: Mol Pharmacol. 1999 Mar;55(3):564-74
references.pmid: 10051542
references.citation: Nature. 1999 Jul 22;400(6742):371-5
references.pmid: 10432116
references.citation: J Neurosci Methods. 1996 May;66(1):1-11
references.pmid: 8794935
references.citation: J Clin Psychopharmacol. 2008 Feb;28(1):45-51
references.pmid: 18204340
references.citation: J Med Chem. 2007 Oct 18;50(21):5076-89
references.pmid: 17867665
references.citation: Psychopharmacology (Berl). 2008 Mar;196(4):533-42
references.pmid: 17985117
references.citation: Neuropharmacology. 2009 May-Jun;56(6-7):944-55
references.pmid: 19371585
references.citation: Synapse. 2001 Feb;39(2):161-6
references.pmid: 11180503
references.citation: Eur J Neurosci. 2005 Jun;21(12):3427-38
references.pmid: 16026480
references.citation: Expert Opin Investig Drugs. 2007 Jan;16(1):45-57
references.pmid: 17155853
references.citation: Brain Res. 1995 May 29;681(1-2):1-7
references.pmid: 7552265
references.citation: Int J Neuropsychopharmacol. 2006 Oct;9(5):585-602
references.pmid: 16942635
references.citation: Eur J Pharmacol. 1996 Jul 25;308(3):261-9
references.pmid: 8858296
references.citation: J Med Chem. 2007 Aug 23;50(17):4135-46
references.pmid: 17672446
references.citation: Trends Pharmacol Sci. 1994 Oct;15(10):374-9
references.pmid: 7809953
references.citation: Neurology. 1999;52(7 Suppl 3):S10-3
references.pmid: 10227604
references.citation: Trends Pharmacol Sci. 1992 May;13(5):177-84
references.pmid: 1604710
references.citation: Brain Res Brain Res Rev. 2005 Jul;49(1):77-105
references.pmid: 15960988
references.citation: Eur J Pharmacol. 2002 May 10;442(3):231-5
references.pmid: 12065076
references.citation: Drug Alcohol Rev. 2008 May;27(3):220-8
references.pmid: 18368602
references.citation: Brain Res Mol Brain Res. 1997 May;45(2):335-9
references.pmid: 9149110
references.citation: Trends Pharmacol Sci. 2002 Apr;23(4):151-3
references.pmid: 11931978
references.citation: J Med Chem. 2009 Apr 23;52(8):2559-70
references.pmid: 19331412
references.citation: Neuropsychopharmacology. 2007 Oct;32(10):2238-47
references.pmid: 17327886
references.citation: J Pharmacol Exp Ther. 2005 Jul;314(1):310-9
references.pmid: 15833897
references.citation: Psychopharmacology (Berl). 2004 Oct;176(1):57-65
references.pmid: 15083257